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ABSTRACT
Pain presents in 80% of patients with advanced
cancer, and 30% have periods of increased pain
due to fluctuating intensity, known as
breakthrough cancer pain (BTcP). BTcP is high-
intensity, short-duration pain occurring in
several episodes per day and is non-responsive
to treatment. The clinical approach to BTcP
is variable. A review of the literature
was performed to provide clinicians and
practitioners with a rational synthesis of the
ongoing scientific debate on BTcP and to
provide a basis for optimal clinical approach
to BTcP in adult Italian patients. Data show that
circadian exacerbations of pain should
be carefully monitored, differentiating, if
possible, between fluctuations of background
pain (BP), end-of-dose effect, and BTcP. BTcP
should be monitored in all care contexts in
clinical practice and each care facility must have
all the medications and products approved for
use in BTcP at their disposal. Data show that
knowledge about medications for BTcP is
lacking: medications for BTcP treatment are
not interchangeable, although containing the
same active substance; each physician must
know the specific characteristics of each
medication, its pharmacological properties,
limitations in clinical practice, specifics
relating to titration and repeatability of
administration, and technical specifics relating
to the accessibility and delivery. Importantly,
before choosing a rapid-onset opioid (ROO),
it is essential to deeply understand the status
of patient and the characteristics of their
family unit/caregivers, taking into account
the patient’s progressive loss of autonomy
and/or cognitive-relational functionality. When
BTcP therapy is initiated or changed, special
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attention must be paid to training the patient
and family members/caregivers, providing clear
instructions regarding the timing of drug
administration. The patient must already
be treated effectively with opioids before
introducing ROOs for control of BTcP.
Keywords: Breakthrough cancer pain (BTcP);
Cancer; Fentanyl; Pain; Pain exacerbation;
Palliative care
INTRODUCTION
It is commonly experienced by clinicians
involved in cancer treatment, especially for
patients in the advanced and progressive
phase of disease, that pain is not always
adequately controlled, even when up-to-date
treatment guidelines are followed. One of the
most frequent causes of such difficulty relates to
the observation that pain occurs in 80% of
cancer patients in an advanced stage of disease
and in 30% of cases with a high intensity of
pain [1]. These pain fluctuations are often
unexpected and unpredictable [1]. Sometimes,
they can be due to predictable, although
unavoidable, causes such as voluntary motor
activity or automatic changes in sleeping
position [2].
In the last 20 years, the objective analysis of
the clinical pathway in oncologic patients has
allowed to identify, within these pain
variations, a specific pain syndrome called
breakthrough cancer pain (BTcP) by the
international scientific community, also
defined as intense episodic pain (dolore
episodico intenso) by Italian physicians.
BTcP is differentiated from background pain
(BP) variations by: (a) its high intensity,
generally C7 in a Numerical Rating Scale
(NRS) 0–10; (b) a short time between onset
and peak of intensity (a few minutes); (c) a
short duration (approximately 60 min); (d) its
potential recurrence during 24 h (3–4 daily
episodes in most patients); and (e) non-
responsiveness to treatment for BP, even when
the daily dose of medication (primarily opioids)
is increased [3]. Even today, the clinical
approach to BTcP varies markedly among
physicians, from a complete negation of the
syndrome to its over-estimation.
The primary objective of this paper was to
provide clinicians and practitioners involved in
treatment of cancer patients in different roles
with a reasoned synthesis of the ongoing
scientific debate on BTcP. The debate is
dynamic, as inferred from the considerable
body of literature annually produced at both
international and national level, and from the
numerous scientific meetings during congresses
or single-topic meetings held each year. Our
analysis aims at providing the basis for an
optimal clinical approach to BTcP.
METHODS
This paper is the result of a debate among
three Italian experts—two clinicians and a
pharmacologist—operating in pain therapy
and palliative care. The integration of an
analysis of existing literature and clinical
experience of the authors offers a rational and
up-to-date support to all who are asked to
provide an adequate treatment for pain to
over 180,000 oncologic patients in Italy. Some
of these are terminally ill cancer patients
experiencing the so-called advanced and
progressive stage of disease, no longer
manageable with etiologic treatments. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
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PATHOPHYSIOLOGY OF BTcP
Definitions of BTcP
Despite increasing availability of ever more
accurate tools and studies, the clinical features
and physiopathogenesis of BTcP remain
unclear. Over time, numerous differing BTcP
definitions have been reported in the literature.
All of them, however, derive from the first
definition of the clinical profile of BTcP
described as ‘‘a transitory flare of pain in the
setting of chronic pain managed with opioid
therapy’’ [4]. In 1995, BTcP was described as ‘‘an
exacerbation of pain that occurs spontaneously
or which accompanies a specific activity’’ [5].
More recently, BTcP has been defined as ‘‘a pain
of short duration, more or less intense, which
breaks through the pain barrier provided by
analgesic medications managing BP’’ [6, 7].
According to one of the more recent and
comprehensive definitions, ‘‘breakthrough pain
is a transient exacerbation of pain that occurs
either spontaneously, or in relation to a specific
predictable or unpredictable trigger, despite
relatively stable and adequately controlled
background pain’’ [e.g., background pain
controlled through an around-the-clock (ATC)
dosing, that is drug administration at fixed
times] [2]. A year earlier, the idea of BTcP having
a different causal mechanism than for BP was
introduced: ‘‘Breakthrough pain can be an
exacerbation of the baseline pain OR it can be
a pain with a different cause from that of the
baseline pain’’ [1]. According to pathogenetic
interpretation, BTcP should no longer be
considered a fluctuation or a sudden variation
of BP, but a type of pain triggered by a different
causal mechanism, superimposed on the pre-
existing mechanism causing BP.
The definition by Davies et al. [2] has
been revised in recent publications [3, 8]. An
extensive survey of clinicians working in
selected Italian centers for palliative care
and pain therapy led to reformulate
recommendations for the best practice in BTcP
diagnosis and treatment. The collected opinions
and suggestions resulted in a more complex
and analytic BTcP definition: ‘‘BTcP is an
exacerbation of pain of high intensity, with a
difference of at least 3 points compared to
background pain and with an absolute intensity
C7 points (measured with a NRS), with a daily
frequency typically not exceeding 4 episodes,
which occur either spontaneously or as a result
of predictable or unpredictable triggering
factors, despite an adequately controlled
background pain (average pain in the last
24 h, B4 points) with an around the clock
opioid therapy’’ [3]. Although deriving from
an exclusively Italian expert panel and not yet
validated by an international consensus, this
definition is useful for enabling clinicians
to understand BTcP characteristics and to
better guide them in recognizing its presence.
The definition specifically describes the
phenomenon of BTcP and highlights both
clinical and pathogenetic aspects.
Thus, according to previously reported
considerations, BTcP cannot be recognized
as a single nosological entity, but includes
different and changing pathogenetic mechanisms
justifying its sub-typing [3].
BTcP: Clinical Characteristics
and Prevalence
The poorly defined and variable clinical
characteristics of BTcP, together with
imprecise prevalence data, account for the
discordant taxonomy for this type of pain.
Data show that BTcP is present in 40–80% of
patients, characterized by a rapid onset
(\3 min), a short duration (median 30 min),
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and a daily frequency of 4–7 episodes/day
[9–11]. The prevalence between 40% and 80%
is inaccurate. Furthermore, the definitions
‘‘rapid onset’’ and ‘‘short duration’’ are both
qualitative and the daily average frequency,
between 4 and 7 episodes, is too wide.
For clinical purposes, representation of BTcP
types is shown in Fig. 1: BTcP is usually classified
into a stimulus-independent or spontaneous
BTcP, a stimulus-dependent or evoked BTcP
and a BTcP related to the therapeutic approach
or to procedural interventions [12]. Evoked
BTcP may be volitional or non-volitional.
Evoked volitional BTcP may be related to
normally painful stimuli (e.g., pinprick,
application of intense heat) or to stimuli that
do not normally provoke pain (allodynia). The
attribute ‘‘non-volitional’’ refers to mechanisms
regulated by the autonomous nervous system,
such as intestinal peristalsis, arterial pulsation,
and body temperature.
As shown in Fig. 1, one pain type originally
traced to BTcP is closely related to the loss of
antalgic efficacy caused by the end-of-dose
effect; according to available data, this type of
pain would account for 17–30% of episodes at
first classified as BTcP [13]. In these patients, a
pain exacerbation would be brought on by an
inadequate treatment of BP, in terms of dose/
duration of efficacy/schedule of administration
of medications used according to the ATC plan,
at fixed times daily.
Zeppetella [13], and most other authors, do
not include end-of-dose pain episodes among
BTcP, as a fundamental requirement of BTcP is
that BP must be properly controlled. This type
of pain is due to inadequate BP therapy and
should be treated in different ways.
Fig. 1 Clinical types and characteristics of breakthrough cancer pain [12]. Reproduced with permission from Svendsen et al
[12]
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Conversely, most authors include the incident
pain in BTcP, characterized by a prevalence of
50–60%. It is produced by a causal stimulus
superimposing on a basal pathological condition
and can be distinguished in: (a) predictable
incident pain caused by a gentle pressure, a
movement, cough, swallowing, chewing, etc.,
which can be predicted and adequately
pre-treated; and (b) unpredictable incident
pain, for example associated with intestinal
peristalsis, a spastic contraction of the hollow
viscus (e.g., pain of colic type), an ischemic
event, etc. [2].
Lastly, idiopathic or spontaneous pain
(20–50% prevalence) is a type of BTcP not
associated with a specific, recognizable
pathogenesis. The concept of ‘‘spontaneous’’ is
related to a total lowering of the receptor
threshold so that the pain is present even in
the absence of external stimuli [13].
According to recommendations provided by
the task force of the Association for Palliative
Medicine of Great Britain and Ireland, a close
relationship exists between BTcP definition
and physiopathological classification [2]:
BTcP is deemed a range of entities, the
physiopathogenetic mechanisms involved are
multiple (nociceptive, neuropathic, and mixed),
and idiopathic or spontaneous BTcP should
be differentiated from incident BTcP, with
the latter further divided into subcategories
(Table 1) [2, 8].
The difficulty, not fully solved in clinical
practice, is due to the incapability to distinguish
a BP variation from an actual BTcP episode.
Thus, therapeutic behaviors differ substantially;
for example, some authors inappropriately treat
all circadian flares of pain with rescue opioids,
as BP fluctuations [8].
BTcP: Pathogenesis
Pathogenesis underlying BTcP onset is probably
heterogeneous. BTcP may depend on stimuli
responsible for a sudden excess of afferent nerve
impulses or on alterations originating in the
somatosensory system [14]. BTcP pathogenetic
hypotheses are shown in Table 2.
A first possible mechanism involved in BTcP
onset could be related to a transient increase in
Table 1 APM classiﬁcation of BTcP categories and sub-categories, related to the pathogenetic mechanisms
Types of BTcP Subtypes
Idiopathic or spontaneous pain:




The episodes are related to an identiﬁable precipitant, and so are
somewhat predictable
Volitional incident pain:
Brought on by a voluntary act (e.g., walking)
Non-volitional pain:
Brought on by an involuntary act (e.g.,
coughing)
Procedural pain:
Related to a therapeutic intervention (e.g.,
wound dressing)
APM Association for Palliative Medicine of Great Britain and Ireland, BTcP breakthrough cancer pain
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afferent stimuli secondary to nearby tissue
involvement following primary (or secondary)
neoplastic lesion-dependent factors, or following
the occurrence of additional algogenic stimuli
originating from neoplastic tissue. The neoplastic
mass may cause a transient stimulation through
involvement of nearby sensitive structures (e.g.,
nerve compression). At the same time, a new
stimulus (e.g., secondary to a movement or
swallowing), not necessarily painful in normal
conditions, can exceed the nociceptor threshold
and produce an intense pain (mechanism:
allodynia from non-painful stimulus and
hyperalgesia from painful stimulus). One of the
clinical characteristics of this type of pain is that
it can be confined to the originating tissue or,
when the neoplasm affects adjacent tissues, the
pain also occurs in other sites (e.g., innervation
area of nerve structures involved). Pain duration
is generally linked to the stimulus duration (e.g.,
movement, posture or changes of posture,
defecation, etc.) [15].
A second possible mechanism involved in
the occurrence of BTcP is the increase in
peripheral sensitization of tissue terminals, of
nociceptors or ectopic sites formed following
cancer-induced anatomical-functional changes
that lower the nociceptor or ectopic site
threshold [15].
A third mechanism for BTcP onset is an
increase in spinal neuron sensitization—the
central sensitization—following the spatial–
temporal increase of afferents originating from
peripheral receptors, not activated in normal
conditions. This can happen in cases where
sensitive input delivered by the C fibers
increases, following the engagement of the so-
called ‘‘silent’’ nociceptors [16]. Silent nociceptors
are located in the visceral system in large
numbers, for example in the intestine, and so
Table 2 Potential physiopathogenetic mechanisms in BTcP [14]
Excess of stimuli Modiﬁcations of the somatosensorial system
Produced by: Stimuli that act on injured tissue
or stimuli induced by pathological tissue on
adjacent tissues
Produced by: Lowering of the
nociceptor threshold or of ectopic
sites with allodynia or hyperalgesia
Produced by: Transient increase
of sensitivity in spinal
neurons
Duration: Short and closely dependent on the
stimulus duration (movement, posture, and/or
its variations, defecation, etc.)
Type: Increase of BP with the same
characteristics or occurrence of a different
kind of pain for the involvement of other
sensitive structures (compression of nearby
tissues)
Site: Same site as BP or in tissues directly
affected by the neoplasm or as a result of its
action on the sensitive nervous system
stimulating the area/areas of perceived pain
Duration: Variable
Type: Increase of BP, with the same
characteristics
Site: Same site as BP
Duration: Not short
Type: Characteristics
sometimes different to BP
Site: A greater extension of BP
and occurrence of reported
pain in distant areas
BP background pain, BTcP breakthrough cancer pain
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are not activated under physiological conditions
(e.g., in the absence of chronic inflammation).
The Italian Breakthrough/Episodic Pain
Study Group provided important data on
various BTcP effects in different body regions,
indirectly confirming the third pathogenetic
mechanism: BTcP would occur more frequently
in the gastrointestinal and urogenital tracts, in
the breast and in the lung, because these are
anatomical structures richer in silent receptors
and Ad fibers, activated by mechanical and
chemical stimuli linked to the presence of
neoplastic tissue [17].
If pain is due to the third mechanism, precisely
because of the functional characteristics of the
spinal neurons which have been sensitized, the
perception of pain extends into broader areas than
BP and persists for a longer time; it differs from
what occurs when the first two ‘‘peripheral’’
mechanisms are involved [18].
According to this analysis of BTcP
pathogenesis, when BTcP is located in the
BP area, it is probably due to peripheral
mechanisms. If sudden acute exacerbation
is perceived in a more extensive area than
that of BP (without following any particular
innervation or organ area), probably the spinal
and supraspinal neuronal systems are already
predominantly involved [18].
Lastly, the occurrence of a sudden pain flare,
even with BTcP characteristics, in an area
different from the main neoplasm may be
secondary to a metastatic localization.
PHARMACOLOGICAL ASPECTS
AND BTcP
Among the administration routes used for
fentanyl—the active substance mainly used for
treating BTcP—the transmucosal routes (buccal,
sublingual, or nasal) are the most common.
Characteristics differentiating the
transmucosal routes used to administer fentanyl
and the preparations currently available in Italy
are analyzed below.
Oral Mucosa: General Characteristics
and Transmucosal Routes
of Administration
The oral mucosa is provided with physiological
properties that are well suited to pharmacological
administration, by virtue of its wide surface,
uniform temperature, high vascularization, and
permeability. It therefore offers favorable
conditions for rapid absorption, representing an
ideal administration route particularly suitable
for pathological states that require a rapid
therapeutic response, such as BTcP. Oral
transmucosal administration also excludes the
liver filter, eliminating the first-pass effect and
accelerating therapeutic action [19].
Importantly, epithelial cells forming oral
mucosa are not in contact with each other
through tight junctions (typical intestinal and
nasal mucosa junctions) but through
desmosomes and hemidesmosomes, loose
intercellular junctions which make the
transport and flux of substances easier [19].
In the oral cavity, we can find separate areas
pertaining to the palatal mucosa, the gingival
mucosa, the so-called buccal mucosa pertaining
to the cheeks and the sublingual mucosa.
Sublingual and buccal mucosae, not keratinized,
better work for the absorption of substances;
however, the greater thickness of the buccal
mucosa, corresponding to 500–600 lm, reduces
its permeability [19]. The reduced thickness and
the high degree of permeability of the sublingual
mucosa, compared to the buccal mucosa, make
this area the most favorable for absorption of
substances [19].
Adv Ther (2014) 31:657–682 663
A more thorough exploration of the
multilayered epithelium lining the oral
mucosa allows to distinguish the layer formed
by the so-called prickle cells or spinous cells
from which granules of phospholipid material
are interposed and disseminated among the
epithelial cells (Fig. 2). The phospholipidic
composition of this substance, although partly
a barrier, helps to create a mobile intercellular
space allowing the flow of substances [19].
In short, two transit routes through the oral
mucosa may be recognized for substances
as well as for medications: the transcellular
route, a pathway for liposoluble substances
(such as fentanyl), able to pass through the
cell membranes; and the paracellular route,
preferred by more water-soluble substances,
which flow through the intercellular
phospholipid material (Fig. 3) [19].
The number of medications administered
orally that can take advantage of the transcellular
route is limited because these substances must
have certain physical and chemical properties
dominated by a precise balance between water
solubility and lipophilicity [20].
An additional element implied in substance
absorption through the oral mucosa is
represented by saliva, which has multiple
physiological functions. Salivary glands
collectively produce more than 1 L of saliva
per day. They are classified into major and
minor salivary glands. The former are mainly
responsible for the aqueous component of
saliva, whereas the latter, and particularly the
sublingual glands, are responsible for the
viscous component of saliva, which is
enriched in mucins [20].
Fig. 3 Transit routes for substances through the oral
mucosa [19]. Reproduced with permission from Campisi
et al. [19]
Fig. 2 Stratiﬁcation of the oral mucosa [19]. Reproduced with permission from Campisi et al. [19]
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The Sublingual Administration Route
A study carried out in 1998 reported that,
although relatively more permeable than the
buccal mucosa, the sublingual mucosa does not
provide a suitable transmucosal administration
route: the sublingual region is devoid of
an underlying muscular reinforcement and
support structure, which is present in the
buccal mucosa and confers fixedness and
firmness to the epithelium [20]. Furthermore,
the sublingual epithelium is constantly washed
by huge amounts of saliva that makes the
persistence of the drugs under the tongue
difficult. Thus, in accordance with this study,
the sublingual mucosa, while ensuring a rapid
onset of pharmacological action because of its
high permeability and abundant blood supply,
would offer an effective route of administration
only for quickly absorbed medications [21].
However, drug delivery can also be affected
by the concentration of mucus in the saliva;
when the medication adheres to mucus it does
not undergo easy removal by saliva, but its
contact with mucosa epithelium lasts longer
and its absorption continues with more efficacy.
Mucoadhesive substances have been formulated
to block the medication at the sublingual level
[22].
A recent study showed that transmucosal
administration efficiency is limited by factors
that support the presence of free, and therefore
ready to be swallowed, medication in the
oral cavity [23]. Among these factors, salivary
secretion in its aqueous component plays a
major role as it causes the release of medication
in the oral cavity. However, if the medication
adheres to the mucosa, absorption is guaranteed
and systemic exposure will be largely
determined by the physical and chemical
properties of the medication [23].
It has been reported that buccal and
sublingual fat may absorb buprenorphine, thus
delaying its plasma level increase and half-life
[24]. Since fentanyl shares similar lipophilic
properties, it is possible that buccal fat
retention occurs. However, to the best of our
knowledge, this does not seem to be a major
determinant in the absorption of oral
transmucosal fentanyl.
Pharmacological Properties of Fentanyl
Pharmacodynamics
Fentanyl, a full l-opioid receptor agonist, is a
synthetic opioid with rapid onset of action and
short duration (indicated for BTcP) and with a
potency 50–100 times greater than that of
morphine. In oral transmucosal formulations,
its analgesic efficacy, proportional to the
plasma concentration, occurs at between 0.3
and 1.2 ng/mL of blood, while respiratory
depression is observed at between 10 and
20 ng/mL [25].
Pharmacokinetics
Fentanyl is a highly lipophilic molecule,
capable of rapidly crossing the blood–brain
barrier, which undergoes a rapid sublingual
absorption, and is metabolized by CYP3A4,
a cytochrome largely responsible for
pharmacological interactions; therefore,
particular attention must be paid to
concomitant medications [25]. Furthermore, it
should be taken in consideration that fentanyl
kinetics may be affected over time by
accumulation in fat and muscle, that, when
saturated after chronic and repeated dosing,
may cause a prolongation of fentanyl half-life,
that, in turn, might be life-threatening.
Fentanyl is available in Italy in the following
formulations:
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– oral transmucosal fentanyl citrate (ACTIQ,
TEVA, Milan, Italy);
– fentanyl buccal tablets (EFFENTORA,
Cephalon Europe, now TEVA, Haarlem, The
Netherlands);
– fentanyl sublingual tablets (ABSTRAL,
ProStrakan, Galashiels, UK);
– fentanyl intranasal spray (INSTANYL,
Takeda Pharmaceuticals, Zurich,
Switzerland); and
– fentanyl intranasal spray with pectin
(PecFent, Archimedes Pharma, Reading UK).
In Italy, since 2014, the fentanyl BioErodible
MucoAdhesive (BEMA) disk (BREAKYL, Meda
Pharma GmbH & Co. KG, Bad Homburg,
Germany) is available, while fentanyl sublingual
spray is not yet available. Each administration
route offers benefits and risks, as shown in
Table 3 [25–32].
Buccal and Sublingual Formulations: Data
From the Literature
A recently published review compared the
pharmacokinetic profile of two different
transmucosal formulations and an intranasal
formulation of fentanyl (Actiq, Effentora, and
Instanyl, respectively), emphasizing that the
formulation should be selected according to
patient needs, the evolution of pain, and to its
onset and persistence [33].
A study carried out in 2006 assessed the
bioequivalence of equal doses of fentanyl via
the buccal route when administered in four
tablets of 100 lg or in a single tablet of 400 lg
[34]. The study showed that 400 lg of Effentora
in a single tablet and four Effentora tablets each
of 100 lg, administered via the buccal route are
not bioequivalent by virtue of the different
absorption surfaces exposed [34]. In spite of
this evidence, a study carried out in 2008
demonstrated the bioequivalence between
buccal and sublingual use of Effentora in
400 lg tablets in healthy volunteers [35]. This is
in contrast with the idea that if a medication
with no mucoadhesive molecules is placed under
the tongue, its absorption should be reduced
versus buccal administration (Fig. 4a, b) [35].
Furthermore, the findings of this study could be
considered valid only for the dosage of 400 lg
and could not be extrapolated to other dosages;
the bioequivalence refers only to 400 lg and the
bioequivalence of other dosages would require
confirmation in a clinical trial.
In agreement with this statement, a recent
paper published in the New England Journal
of Medicine by members of the US Food and
Drug Administration shows that budeprion, the
generic version of bupropion, was bioequivalent
to the branded drug at the dosage of 150 mg,
but not at the dosage of 300 mg, in fact
suggesting that bioequivalence at different
dosages should be demonstrated by clinical
studies and not extrapolated [36].
There are substantial differences between
medications formulated for sublingual
administration, such as Abstral, and buccal
administration, such as Effentora. Unlike
Abstral, Effentora excipients do not include
the mucoadhesives that give Abstral
sublingual absorption capability; specifically,
crosscarmellose, a powerful disintegrant
improver of absorption with bio-mucoadhesive
action, and the silicified microcrystalline
cellulose, a tablet binder and, concurrently,
an agent promoting disintegration and bio-
mucoadhesion [37].
Diversification of Therapeutic Approaches
in BTcP
In 2009, specific recommendations for the
management of BTcP including an algorithm
for dose titration were published [2]. On lack of
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Table 3 Advantages and disadvantages of different routes for available BTcP treatments [25]
Administration route
available formulations






• The mucosally absorbed dose (25%)
bypasses hepatic ﬁrst-pass
metabolism
• Rapid onset of action
• Cessation of drug administration is
feasible if toxicity develops
• Can be used for pediatric and
geriatric patientsa
• Can be used by patients who are
unable to swallow or ﬁnd
medications difﬁcult to swallow due
to nausea/vomiting
• Relatively low surface area for
absorption
• May be difﬁcult for patients
with dry mouth/mucositis
• The ‘‘lollipop’’ may be
perceived as childish
• Potential for dental decay
with prolonged use
• Absorption can be variable
• Patients may require training
on correct use











• The mucosally absorbed dose (48%
with buccal tablets; 51% with
soluble ﬁlm) bypasses hepatic ﬁrst-
pass metabolism
• Rapid onset of action
• Greater bioavailability than oral
transmucosal products
• Can be used by patients who are
unable to swallow or ﬁnd
medications difﬁcult to swallow due
to nausea/vomiting
• Lower permeability via buccal
membrane compared with
sublingual membrane
• Smaller surface area for
absorption














• The mucosally absorbed dose
bypasses hepatic ﬁrst-pass
metabolism
• Rapid onset of action
• Can be used by patients who are
unable to swallow or ﬁnd
medications difﬁcult to swallow due
to nausea/vomiting
• May be difﬁcult for patients
with dry mouth/mucositis
• Drug and delivery system may
be ingested in saliva




Adv Ther (2014) 31:657–682 667
pain control or in the presence of adverse
effects with oral transmucosally administered
opioids, the medication dose should be titrated.
Titration is essential, because the characteristics
of the oral mucosa are different among
patients and BTcP management needs to be
personalized; this implies that adequate
therapeutic tools must be available. The
currently available tools are multiple and
varied, but the superiority of one product
compared to another cannot be stated, rather
only the validity and efficacy of one product in
relation to the needs, individual characteristics,
and pain of an individual patient. Therefore, it
is not correct to consider different formulations
as equivalent: sublingual administrations must
be recognized as such, and distinguished from
other types of transmucosal administration.
Maintaining a diversification of therapeutic
approaches, on the basis of patient’s biological
complexity and the pharmacological
differences of each transmucosal formulation,
allows the patient to be offered an extensive
range of therapeutic equipment from which to
draw for individual needs.
The Intranasal Route
The intranasal route is another important non-
invasive route for systemic administration and,
like the oral transmucosal route, offers benefits
of rapid absorption, absence of first-pass
metabolism, and a rapid therapeutic response.
The respiratory area around the inferior
turbinate is the area of maximum absorption











Fentanyl pectin nasal spray
(LAZANDA, Archimedes
Pharma, Reading UK)
• The systemically absorbed dose
bypasses hepatic ﬁrst-pass
metabolism
• Can be administered by caregivers
• Rapid onset of action
• Convenient
• Can be used by patients who are
unable to swallow or ﬁnd
medications difﬁcult to swallow due
to nausea/vomiting
• Patients may require training
in the correct administration
technique for intranasal sprays
• Potential for application-site
adverse effects including nasal
irritation
• Potentially unsuitable for
patients with colds or illnesses
that result in changes to the
nasal mucosa
• Quantity of drug absorbed
may be variable
• Nasal drip or swallowing can
affect absorption
• May be difﬁcult for patients
lacking manual dexterity





BTcP breakthrough cancer pain
a ACTIQ is not indicated for use in pediatric patients
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permeability, and abundant vascularization
[38]. The epithelium lining the nasal cavity
consists of basal cells, ciliated cells and mucus-
secreting cells (‘‘goblet cells’’). Unlike the oral
mucosa, the intercellular junctions are tight,
restricting the passage of substances [38].
Transcellular and paracellular passage can be
recognized.
The currently available spray formulation,
Instanyl, in which the medication is passively
absorbed, presents a limitation due to the
variable amount of solution which enters the
pharynx and then is swallowed. In an attempt to
overcome this problem, a new formulation of
fentanyl was devised in combination with
pectin, a mucoadhesive polymer, which forms
a gel in the nasal cavity and from which the
active substance is released and absorbed. Hence,
even in nasal transmucosal administration,
systems based on the use of mucoadhesive
substances have been developed to control and
increase systemic absorption [38].
PRACTICAL ASPECTS OF BTcP
TREATMENT
General Premises
Clinical and pharmacological aspects,
previously analyzed, are crucial to understand
Fig. 4 Fentanyl plasmatic concentrations and pharmacokinetic
parameters related to buccal and sublingual routes.
a Logarithm of the plasmatic concentrations of fentanyl
after administration of a single dose of 400 lg in tablet via
the buccal and sublingual routes and 4. b The relative
pharmacokinetic parameters [35]. FBT fentanyl buccal
tablet. Reproduced with permission from Darwish et al.
[35]
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why in clinical practice an optimal therapeutic
approach for BTcP should follow different rules
and principles from those for BP. The analgesic
therapy for BTcP should always be based on an
integration of the two therapeutic schemes, for
BP and BTcP. On the other hand, in BTcP
treatment, several variables may influence the
initial choice of the active substance to be used,
the possible switch, and the administration
route and method as well: characteristics of
patient, family and support group (e.g., a
professional caregiver), the composition of the
care team, the therapeutic setting, and the
organizational-management-economic and
local regulatory framework, more broadly
defined as ‘‘context’’ (Table 4).
BTcP represents a widespread and
undertreated clinical problem in cancer
patients, even in cases where BP is well
controlled by analgesic therapy [2]. It is a
common clinical observation, however, that is
not always easy to distinguish between
variations of BP and BTcP. A clear definition of
‘‘adequate control of BP’’ is not available in
scientific literature, although considered by all
guidelines as an essential condition to start a
specific treatment for BTcP. In our opinion, from
a clinical point of view ‘‘adequate pain control’’,
both in BP and in BTcP, means an antalgic effect
which decreases the pain intensity to a value B2
on a NRS scale. This is true for any value of pain
intensity—BP or BTcP—before the start of drug
treatment. Therefore, it is advisable that cancer
patients with pain be constantly observed and
monitored from the initial planning phase of
opioid treatment, leaving the decision to the
evaluation and experience of each clinician to
use rapid-onset opioids (ROOs) or other
analgesic systems, such as patient-controlled
analgesia (PCA), but suggesting that parenteral
medicines be used in the hospital setting only
[39–41].
The availability of analgesic medications—
opioids in particular—varies among countries
due to different registration and marketing
policies; some preparations, much used in a
country, may not to be available elsewhere. In
Italy, for example, morphine, for daily single
oral administration, or immediate-release
oxycodone is not available. These differences
are also present in Italy between regions, and
also between local health authorities and
hospitals. At present in Italy, only general
practitioners (GPs) are authorized to prescribe
any approved opioid, thereby ensuring
reimbursement of related costs to the patient
and family by the Italian National Health
System. Lastly in Italy, unlike in other
European countries, pain exacerbations, even
in a relatively advanced and progressive cancer
stage, are often treated with non-steroidal anti-
inflammatory drugs (NSAIDs), typically via the
intramuscular route, as first-line approach for
BTcP [42]. These are inappropriate therapeutic
schemes, not recommended in the latest
treatment guidelines, but very widely adopted,
especially in hospitals. The real impact
of NSAID use could be more thoroughly
investigated in both qualitative and
quantitative terms [43].
Specific Aspects
All variables listed in Table 4 should be
considered in the clinical approach to BTcP.
This type of ‘‘global’’ approach must be
implemented in both phases of the clinical
pathway: (a) in the initial phase of selection of
the active substance and administration route;
and (b) in the subsequent phases, characterized
by the achievement of the optimal daily dosage,
even in case of switching due to inefficacy,
intolerance, or difficulty in administration. It
should also be noted that the concept of opioid
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rotation or opioid switch has developed as part
of BP treatment and has been more studied in
that area [39] than in BTcP.
The misperception that ROO-administration
systems may be superimposed in clinical use as
they all release an identical active molecule
(fentanyl) is commonly held, and the idea that
each product has its own specificity and
appropriateness of use has not yet sufficiently
disseminated. We need to arrive at a rational




1. Patient • See Table 6
2. Family unit • See Table 7
• Number of members with caregiver role
• Internal relational features of the family unit
• Relational features with the care team
3. Caregiver • See Table 7
• Family caregiver
• Non-family (professional) caregiver
4. Care Team • Composition of team
• Level of knowledge (team directly or indirectly involved in palliative care)
• Level of operational autonomy also related to the setting
• Time available
• Preferences for available medications based on previous experience
5. Therapeutic
setting
• Home care: GP provided palliative home care model or in Hospital-at-Home specialist palliative
care model
• Hospice
• Specialized stay unit (not palliative care)






• Health and social services facility (e.g., residential care home)
6. Context • Variables relative to the organizational-management-economic aspects
• Regulatory variables (e.g., prescriptive autonomy)
BTcP breakthrough cancer pain, GP general practitioner
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choice based on therapy personalization
through a careful evaluation of the variables
analyzed below, for which a definition as ‘‘target
BTcP opioid therapy’’ is suggested.
Possibly the most widespread factors of
inappropriateness in treating BTcP currently in
Italy are as follows:
1. Lack of clinical recognition of this pain
entity, due to an inadequate mode of
detection and daily monitoring of pain,
even though this is an obligation provided
for by art. 7 of Law 38/2010 [44]. This
serious shortcoming clearly emerges each
year from the Reports that the Minister of
Health must communicate to Parliament to
comply with art. 11 of Law 38/2010 [45].
2. Use of NSAIDs, especially via the
intramuscular route, even for BTcP with
repeated daily episodes.
3. Oral use of weak opioids even in the case of
intense exacerbations.
4. ‘‘Dogmatic’’ use of oral immediate-release
morphine formulations, regardless of the
comparative assessment of efficacy for each
patient, especially concerning the rapidity
of action and the effectiveness profile
(efficacy/tolerability ratio) [39, 46–48].
5. Constant use of the same ROO system of
fentanyl, among the six ones approved for
clinical use in Italy since 2005 (Table 5),
regardless of prior assessment of clinical
situation and patient preference, and of the
potential support offered by patient’s family
or caregiver to the therapeutic team.
The causes of these prescriptive behaviors,
especially those listed in points 3, 4, and 5
above, are often independent on the level of
specific knowledge of clinicians and result from
variables outside of their control, such as a non-
thorough application of pharmacoeconomic
principles by purchasing decision makers. Use
of lower cost medications, such as those
indicated in points 2, 3, and 4, is preferred,
even though it is evident that they do not
always represent the optimal treatment in BTcP.
NSAIDs, for example, are associated with a
large number of toxic effects [49]. In addition,
morphine per os, even in its immediate-release
preparations, has an average time required to
achieve the peak intensity, significantly more
prolonged than ROOs [50]. In the case of BP
fluctuations, short-term oral morphine may
find indications as a rescue medication, i.e.,
necessary to adjust the ATC treatment in
relation to the circadian pain flares [39]. Its
uncritical use, however, in the case of a clear
presence of BTcP, exposes patients to some risks:
(a) the persistence of intense pain, even for
30 min after onset; (b) non-optimal control of
the exacerbation; and (c) pharmacological
effects of morphine needlessly longer than the
duration of the BTcP episode in relation to the
pharmacological and analgesic half-life of the
opioid (3–4 h vs. the average BTcP duration of
60–90 min) [50–52].
Table 5 Rapid-onset opioids (ROO) containing fentanyl
available in Italy for BTcP treatment
Route Acronym Year of ﬁrst
clinical use in
Italy




Sublingual (bioadhesive) SLF 2010
Nasal (aqueous solution) INFS 2011
Nasal pectin FPNS 2011
Oral mucosa (bioadhesive) FBT-B 2014
BTcP breakthrough cancer pain
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Variables Involved in the Therapeutic
Approach: The Patient
From the patient’s point of view, all points in
Table 6 must be carefully taken into account.
In a patient with good cognitive functions
and with reasonable motor activity (especially
in the upper limbs and hands), the choice of
route and system of administration should be
based primarily on their preference. This has
been shown to be feasible in clinical practice
[53]. The patient should be informed and
educated about the four routes (gingival
fornix, sublingual mucosa, oral mucosa, and
nasal mucosa) and the six existing systems [54].
The time dedicated to patient training is
balanced by an increased adhesion of the
patient to the treatment scheme and by the
reduced rates of inefficacy resulting from an
incorrect use of the chosen system. It is also
clear that systems with easier administration
instructions have a greater guarantee of success
in patients who are already stressed by daily
pain and suffering. In a recent European
multicenter study, the oral route was generally
the most appreciated [53].
A recent comparative study among three
fentanyl ROOs (two oral transmucosal and one
nasal), although enrolling a limited number of
patients, showed that the use of a product
specifically developed for sublingual use was the
most appreciated by patients because of its
mucoadhesivity, rapid dissolution, and rapid
absorption [33].
When using the oral route, patients should
be advised that swallowing ROOs before
complete dissolution should be avoided, to
maximize the bioavailability and not to
increase the dosage for a satisfactory analgesic
effect. This may not be easy for the patient, as it
means keeping one or more tablets without
mucoadhesive properties fixed to the oral
mucosa for at least 10–15 min, until a
complete dissolution [33–35].
The use of the ‘‘stick’’ system, first marketed
in Italy in 2005, which sticks to the gingival
fornix, may represent the preferred choice for
some patients. The same consideration can be
made for the two systems that release fentanyl
via the nasal route (in aqueous solution or
pectin), in which the greater rapidity of action
is counterbalanced by the need to have a good
level of skill on the part of the patient in the use
and loading of the specific devices.
Another important aspect is to assess drug-
taking capability during the education and
first-prescription phase, recently defined as
‘‘accessibility’’ [33]. This applies particularly in
relation to the technical specifications of the
Table 6 Non-pharmacological variables relative to the patient to be assessed in the choice of medication for BTcP
treatment
1. Preference for the available administration routes
2. Presence of serious xerostomia or other buccal pathologies
3. Grade of impairment of functional autonomy (e.g., conﬁnement to bed and forced postures)
4. Grade of motor activity impairment (in particular in upper limbs and hands)
5. Presence of buccal automatisms (e.g., biting)
6. Cognitive-relational level
7. State of consciousness
BTcP breakthrough cancer pain
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packaging for each product. So, in daily use,
these apparently simple devices may reduce
accessibility. In the context of palliative care,
it should be remembered that skills and
motor activity of patients may change quickly,
for example, in connection with worsening
of the asthenia, anorexia–cachexia syndrome,
neurological deficit, or with cognitive-relational
changes described below.
An additional variable to be borne in mind in
the choice of medication is the ability of the
patient to maintain the forced postures required
(such as maintenance of the supine position) or
a possible inability to assume a sitting or semi-
sitting position.
Lastly, the methods of titration for the
achievement of effective dose must be
considered. Methods are specific for each ROO
and used correctly in only 42% of the cases
treated [3]. In fact, although some recent studies
have sought to identify a proportional
relationship between the dose of the ATC
opioid used for BP and the initial dosage of
ROO [55], the general rule is to commence with
the lowest available dosage of the chosen ROO
and to gradually increase it until the effective
dose is reached [52]. Such a procedure—‘‘initial
titration’’—should be planned when switching
to another ROO in the case of a progressive
loss of efficacy, after checking that self-
administration had been performed correctly.
It is quite clear that this assumes a certain
importance in the choice by the patient both
during instruction and prescription phases of
the different dosages used during titration for a
quick attainment of the optimal dosage for
BTcP control.
The situation is different in the case of:
(a) patients with cognitive-relational problems,
or (b) with motor activity difficulties, especially
in the upper limbs and hands, or difficulty
with coordination of the complex buccal
motor activity, especially for those subjects
characterized by automatic movements of
buccal ejection of liquids and solids. Especially
in the more advanced stages of the disease, but
also in elderly subjects, unconscious motions of
sucking or ejection of that introduced by others
into their oral cavity may be present.
In the former kind of patients, selection and
method of administration become significant
and imply an operability that is always ‘‘active’’
for the therapeutic team and more and more
‘‘passive’’ on the part of the patient. If the
choice is made not to switch to intravenous
bolus administration of opioids, for these
patients the most appropriate ROOs are those
specifically designed for the sublingual or nasal
route (see also the sections ‘‘Variables Involved
in the Therapeutic Approach: The Care Team’’
and ‘‘Variables Involved in the Therapeutic
Approach: Care Setting’’). In the latter kind of
patients, when difficulties are due to motor
activity, an assessment and the preference of
the patients should always be requested.
Variables Involved in the Therapeutic
Approach: Family and Caregivers
Especially in the context of home care but,
sometimes even for assisted patients in
residential care homes or hospices, the family
unit—and in particular the caregiver—plays an
important role in the evaluation of pain and in
the interaction with the therapeutic team, but
also in drug administration and monitoring of
medication efficacy.
As a rule, an important selection criterion in
taking charge of home care by a palliative
care team is the constant presence of a
family caregiver, but often this prerequisite is
not fulfilled. The sociological composition of
the Italian family, in fact, is increasingly
characterized by the presence of ‘‘expanded’’
family units, with a turnover of different
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relatives in the home during the day; therefore,
the presence of non-family caregivers is
increasingly widespread, without specific
healthcare training and of non-Italian
nationality, culture, and language.
Increasingly, the patient is assisted by an
elderly spouse, who may have problems of
reduced autonomy and physical and
neuropsychic comorbidities that limit their
own ability to support the patient.
Regarding BTcP treatment, the care team
should investigate the potential support that
can be provided by the family unit or caregiver
to formulate a proper therapeutic plan. More
than one caregiver is sometimes involved and
the situation is therefore more complex, so the
course of instruction on the implementation of
therapeutic plans becomes more difficult.
When the patient is compliant and
sufficiently autonomous, the role of caregiver
is more straightforward, limited to checking the
correct BTcP medication is self-administered by
the patient; the caregiver may improve the
accessibility to the medication and verify the
exact doses of drug and their efficacy. The
caregiver can also be very useful in the
titration process aimed at a rapid achievement
of the effective ROO dose. The caregiver may
also interact with the care team, describing
characteristics of pain symptoms, thus
becoming a valid ‘‘third-party’’ observation.
The role of professional caregivers or family
members increases with the worsening of the
disease and the progressive loss of patient
autonomy. If an active support role is not
provided, the risk is an incorrect pain
management during the day, with a
consequent request for ‘‘unscheduled’’ home
visits by the care teams (e.g., GP, palliative care
team, or continuity of care service). In some
cases, especially at night or in weekends,
the uncontrolled pain crises can lead to
unnecessary and inappropriate access to the
Emergency Health Network (e.g., to the hospital
emergency or the community emergency
service). It is recommended that, even in the
initial BTcP treatment prescription, physicians
and nurses take into proper account some
important variables (Table 7).
Comparative studies on currently available
products and their administration by caregivers
or family members, and on their preferences
and assessments, are lacking, but it can be
argued that the initial choice of an effective
product for BTcP treatment can be based on
three main characteristics:
1. Ease of use;
2. A proper use of drug by the patient;
3. The time necessary to check the successful
absorption of the active substance.
The non-mandatory use of specific delivery
devices and the rapidity of drug dissolution
are two variables that, on a case-by-case basis,
should be integrated, in a matrix model, with
the other three characteristics described above
(Table 8).
Variables Involved in the Therapeutic
Approach: The Care Team
The definition of health care team in the
context of palliative care or pain therapy is
very broad, especially due to the absence of
national and regional reference standards.
Differences are observed in reference to each
setting (e.g., the hospice), among different
settings, and, finally, in reference to the so-
called ‘‘intensity of care’’, the number of direct
accesses to the patient by team members in
relation to a pre-defined unit of time (e.g.,
number of days with at least one home visit in
relation to the total number of days of patient
management) [56].
The composition of the care team and the
time available for direct and indirect activities
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assigned to each operator are important
variables to ensure an adequate response to
the needs of patients/families. Their
importance grows when, especially in the
early stages, the diagnostic and therapeutic
interventions require maximum attention to
detail and a high willingness to provide
explanations and correct instructions to the
patient and their families (caregivers). In the
case of BTcP treatment, the patient and their
caregiver should be trained as quickly as
possible in the basic principles (e.g., proper
use of medication, titration, repeat times of
administration, etc.), essential for the
therapeutic success.
Other important differentiating aspects in
the approach to BTcP are the seriousness in
the training and experiential pathway and
the attitude to the innovation and the
introduction of new pharmaceutical preparations
in clinical use.
In the training process, the information
transmitted ‘‘on the job’’ by one operator to
another in the daily debate and audit is very
important and often independent of the
classical modes of training/learning (e.g.,
frontal lessons). In this case also, there are no
specific studies on the attitudes and preferences
of the care team members in relation to the
different settings and treatment options.
From a theoretical point of view, it can be
possible that, when all treatment options are
available, the care team would choose systems
easier to use, that require fewer instructions,
have fewer limitations, less observation of the
patient, and a greater safety level.
Table 8 Matrix scheme useful in the choice of medication for BTcP treatment
A. No need for a
speciﬁc device
B. Rapidity of dissolution of
the product once taken
1. Ease of use (e.g., accessibility, no. of procedural steps for the
administration)
2. Certainty that the patient has taken the medication properly (e.g.,
that it has not been swallowed in the case of oral ROOs)
3. Time to observe the proper absorption of the active substance
BTcP breakthrough cancer pain, ROOs rapid-onset opioids
Table 7 Non-pharmacological variables relative to family members and caregivers for the choice of medication in BTcP
treatment
1. Preference for the available administration routes
2. Any previous experience in administration of drugs
3. Level of intimacy with the patient
4. Grade of possible communication with the patient (see Table 6)
5. Level of comprehension and integration with the care team, especially for modes of administration (device) and titration
6. State of disease progression
7. Presence of one or more family caregivers
BTcP breakthrough cancer pain
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Variables Involved in the Therapeutic
Approach: Care Setting
BTcP could occur in every care setting which
provides assistance to cancer patients in the
advanced stages of therapy: outpatient care, day
hospital, inpatient care in a hospital specialist unit
or hospice, residential care home, or at home. In
the care settings in which a health and social care
team is constantly present and specifically trained
in pain therapy and palliative care, the variables
related to accessibility to the product become
less important, unless the care team delegates
administration of the medication to the patient or
caregiver.
In each setting, in the choice of BTcP
treatment, the referring clinician and care
team should consider all the variables
described, relating to the patient and family
member/caregiver.
The ease of use is a ‘‘transversal’’ variable
in the training and prescription process in
all care settings. Settings characterized by a
greater intensity of care can adopt more
complex treatments including intravenous
administration of bolus of short-term opioids
or infusion systems for PCA methods.
Variables Involved in the Therapeutic
Approach: The Context
The analysis of the specific Italian context in the
care framework offers an opportunity for some
final considerations which may help explain
why, compared to other European countries,
BTcP in Italy is still probably insufficiently and
often improperly treated. According to article
10 of Law 38/2010 [44], GPs can prescribe all
ROO medications currently approved for sale in
Italy; this is not the rule for physicians
operating within health and social welfare
facilities. In some regions, medical specialists,
including palliativists and algologists, are not
authorized to directly prescribe medications so
that the medication costs can be reimbursed by
the regional health system, and they may
prescribe opioids only through the specific
personal prescription book for psychoactive
medications (still in use, despite the changes
introduced by article 10 of Law 38/2010 [44])
or through their own personal prescription
book. In these latter two cases, the patient
and/or family member must purchase the
product in the pharmacy, having no right to
reimbursement by the Italian National Health
Service (NHS).
In some situations, mostly in the public or
private non-profit ‘‘hospital-at-home’’ model,
present only in certain regions (e.g., in
Lombardy), the care team can supply
medications (including ROOs) directly to the
patient at home, provided that the drugs are
included in the regional and/or local pharmacy
formulary, or purchased from the facility to
which the palliative care unit belongs.
A first consequence of these limitations
is that, where the specialist prescription is
not direct but presented as a ‘‘therapeutic
recommendation’’, the patient must have the
medication or medications ‘‘registered’’ by the
GP in the Italian NHS’s prescription book. This
is not always automatic since each practitioner
has their own base of scientific opinions,
knowledge, and experiences. Following the
Law 38/2010 and related training projects, GPs
have acquired a specific cultural basis in treating
pain [57].
Furthermore, only a minority of Italian
regions and local health authorities have
approved their own pharmaceutical formulary;
the mechanisms of authorization for the use
of medications, especially for hospitalized
patients, are markedly diversified among
regions and even within the same region.
Some regions are characterized by a more
‘‘centralized’’ medication policy management,
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sometimes based on the opinion of regional
technical bodies established ‘‘ad hoc’’. In others,
decision makers are more ‘‘peripheral’’,
consisting of the hospital pharmacist or the
local health authority, who can strongly
influence the acquisition/availability of
medicines. In the case of pharmaceutical
products containing the same active
substance, such as fentanyl ROOs, the trend
could be an underestimation of the specificities
of each product, considering them all equal.
The hospital clinician, unlike the GP, still does
not have all pharmaceutical products, generally
having available the products which were
first on the market, or those at lowest cost. In
some situations, the only possibility of BTcP
treatment for specialists is the use of short-term
morphine per os.
Even where a region clearly indicates,
through a specific legislative measure, that the
specialist must have at disposal all the active
substances and products authorized for clinical
use for pain treatment, the opposition to the
application at the peripheral level is strong and
varies between one hospital, and one local
health authority, and another [58].
On the other hand, the technical bodies
within each hospital and each local health
authority since 2001, the Committees for the
Pain-Free Hospital (COSD), subsequently
redefined by article 6 of the Law 38/2010 as
the Committees for the Pain-Free Hospital/
Community (COTSD), with a few exceptions,
have not been able to introduce elements useful
to overcome this critical situation. This is
because they have been established in a
minority of registered healthcare facilities and,
where present, their functioning has not been
continuous and they have no real powers of
changing the actual situation.
Finally, it is clear that the social context and
the degree of social and ‘‘collective’’ sensitivity
to the issue of pain and suffering are elements
which can facilitate or create an obstacle to the
treatment of BTcP.
BRIEF RECOMMENDATIONS
IN THE USE OF MEDICATIONS
IN BTcP
The main points contained in the article are
briefly listed below:
1. Circadian exacerbations of pain should be
carefully monitored, differentiating, if
possible, between changes of BP, end-of-
dose effect, and BTcP.
2. BTcP should be monitored in all care
contexts in clinical practice.
3. Each care facility must have all the
medications and products approved for
use in BTcP; the COSD/COTSD must make
all efforts to achieve this result.
4. Medications for treatment of BTcP are not
automatically interchangeable with one
other, even if they contain the same
active substance.
5. Each practitioner must know the specific
characteristics of each medication and the
differences in pharmacological properties
and possible limitations in clinical
practice.
6. Each practitioner must know the specifics
for titration and the repeatability of
administration (the so-called lock-out
period between one administration and
the other) for each medication used for
BTcP treatment.
7. Each practitioner must know the technical
specifics for accessibility (referring to
the packaging) and delivery of the
medications useful for treatment of BTcP.
8. Physicians and nurses working as a team
must know the prescriptive methods of
the medications useful in treatment of
BTcP.
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9. Before choosing the ROO, particular
attention must be given to gaining
greater knowledge of the variables
concerning the patient and their family
unit/caregivers, taking into account the
progressive loss of autonomy and/or
cognitive-relational functionality of the
patient.
10. When it is decided to commence BTcP
therapy and whenever its therapy is
changed, special attention must be paid
to clearly and sufficiently training patient
and family member/caregiver.
11. The patient must be treated effectively
with major opioids for BP before
introducing ROOs for BTcP.
12. ROOs, at the present state of knowledge,
must not be used in treatment of BTcP
secondary to a non-cancer pathology.
ACKNOWLEDGMENTS
Editorial assistance in the preparation of this
manuscript was provided by Brunilde Iovene,
an independent medical writer, and by Mary
Hines of Springer Healthcare Communications.
Support for this assistance was funded by
ProStrakan Srl. No other funding or
sponsorship was received for this study or
publication of this article. All named authors
meet the ICMJE criteria for authorship for this
manuscript, take responsibility for the integrity
of the work as a whole, and have given final
approval for the version to be published.
Conflict of interest. Cesare Bonezzi has
received research grants from ProStrakan Srl.
Diego Fornasari has received research grants
from ProStrakan Srl. Furio Zucco has received
research grants from ProStrakan Srl.
Compliance with ethics guidelines. This
article does not contain any new studies with
human or animal subjects performed by any of
the authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Hagen NA, Biondo P, Stiles C. Assessment and
management of breakthrough pain in cancer
patients: current approaches and emerging
research. Curr Pain Headache Rep. 2008;12:241–8.
2. Davies A, Dickman A, Reid C, Science Committee
of the Association for Palliative Medicine
of Great Britain and Ireland, et al. The
management of cancer-related breakthrough pain:
recommendations of a task group of the Science
Committee of the Association for Palliative
Medicine of Great Britain and Ireland. Eur J Pain.
2009;13:331–8.
3. Corli C, Pizzuto M, OICP Research Group. Per
qualche dolore in meno… Capire e trattare il
breakthrough cancer pain. Roma: CIC Edizioni
Internazionali; 2011.
4. Portenoy RK, Hagen NA. Breakthrough pain:
definition, prevalence and characteristics. Pain.
1990;41:273–81.
5. Agency for Healthcare Research and Quality.
Management of cancer pain summary. 2001;
evidence report/technology assessment number
35, AHRQ publication number 01-E033.
6. Walsh D. Pharmacological management of cancer
pain. Semin Oncol. 2000;27:45–63.
7. Walsh D, Rivera NI, Davis MP, et al. Strategies for
pain management: Cleveland Clinic Foundation
guidelines for opioid dosing for cancer pain.
Support Cancer Ther. 2004;1:157–64.
8. Zeppetella G. Opioids and breakthrough pain. In:
Fifth Bristol Opioid conference. Bristol University
Press; 2010.
Adv Ther (2014) 31:657–682 679
9. Gomez-Batiste X, Madrid F, Moreno F, et al.
Breakthrough cancer pain: prevalence and
characteristics in patients in Catalonia, Spain.
J Pain Symptom Manag. 2002;24:45–52.
10. Hwang SS, Chang VT, Kasimis B. Cancer
breakthrough pain characteristics and responses to
treatment at a VA medical center. Pain.
2003;101:55–64.
11. Caraceni A, Martini C, Zecca E, et al. Working
Group of an IASP Task Force on Cancer Pain.
Breakthrough pain characteristics and syndromes
in patients with cancer pain. An international
survey. Palliat Med. 2004;18:177–83.
12. Svendsen KB, Andersen S, Arnason S, et al.
Breakthrough pain in malignant and non-
malignant diseases: a review of prevalence,
characteristics and mechanisms. Eur J Pain.
2005;9:195–206.
13. Zeppetella G. Breakthrough pain in cancer patients.
Clin Oncol (R Coll Radiol). 2011;23:393–8.
14. Dickenson A. The neurobiology of chronic pain
states. Anaesth Intensive Care Med. 2013;14:484–7.
15. Wordliczek J, Zajaczkowska R. Mechanisms in
cancer pain. In: Hanna M, Zylicz Z, editors.
Cancer pain. London: Springer; 2013.
16. Cervero F, Meyer RA, Campbell JN. A
psychophysical study of secondary hyperalgesia:
evidence for increased pain to input from
nociceptors. Pain. 1994;58:21–8.
17. Caraceni A, Bertetto O, Labianca R, et al.
Breakthrough/Episodic Pain Italian Study Group.
Episodic (breakthrough) pain prevalence in a
population of cancer pain patients. Comparison of
clinical diagnoses with the QUDEI–Italian
questionnaire for intense episodic pain. J Pain
Symptom Manag. 2012;43:833–41.
18. Woolf CJ. Central sensitization: implications for
the diagnosis and treatment of pain. Pain.
2011;152(3 Suppl):S2–15.
19. Campisi G, Paderni C, Saccone R, et al. Human
buccal mucosa as an innovative site of drug
delivery. Curr Pharm Des. 2010;16:641–52.
20. Narang N, Sharma J. Sublingual mucosa as a route
for systemic drug delivery. Int J Pharm Pharm Sci.
2011;3(Suppl 2):18–22.
21. Shojaei AH. Buccal mucosa as a route for systemic
drug delivery: a review. J Pharm Pharm Sci.
1998;1:15–30.
22. Madhav NV, Shakya AK, Shakya P, Singh K.
Orotransmucosal drug delivery systems: a review.
J Control Release. 2009;140:2–11.
23. Bartlett JA, van der Voort Maarschalk K.
Understanding the oral mucosal absorption and
resulting clinical pharmacokinetics of asenapine.
AAPS PharmSciTech. 2012;13:1110–5.
24. Davis MP, Glare PA, Hardy J, Quigley C, editors.
Opioids in cancer pain. 2nd ed. Oxford: Oxford
University Press; 2009.
25. Smith HS. Considerations in selecting rapid-onset
opioids for the management of breakthrough pain.
J Pain Res. 2013;6:189–200.
26. Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal
fentanyl citrate: randomized, double-blinded,
placebo-controlled trial for treatment of
breakthrough pain in cancer patients. J Natl
Cancer Inst. 1998;90:611–6.
27. Portenoy RK, Taylor D, Messina J, Tremmel L. A
randomized, placebo-controlled study of fentanyl
buccal tablet for breakthrough pain in opioid-
treated patients with cancer. Clin J Pain.
2006;22:805–11.
28. Rauck R, North J, Gever LN, et al. Fentanyl buccal
soluble film (FBSF) for breakthrough pain in
patients with cancer: a randomized, double-blind,
placebo-controlled study. Ann Oncol.
2010;21:1308–14.
29. Rauck RL, Tark M, Reyes E, et al. Efficacy and long-
term tolerability of sublingual fentanyl orally
disintegrating tablet in the treatment of
breakthrough cancer pain. Curr Med Res Opin.
2009;25:2877–85.
30. Rauck R, Reynolds L, Geach J, et al. Efficacy and
safety of fentanyl sublingual spray for the treatment
of breakthrough cancer pain: a randomized,
double-blind, placebo-controlled study. Curr Med
Res Opin. 2012;28:859–70.
31. Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy
and tolerability of intranasal fentanyl spray 50 to
200 microg for breakthrough pain in patients with
cancer: a phase III, multinational, randomized,
double-blind, placebo-controlled, crossover trial
with a 10-month, open-label extension treatment
period. Clin Ther. 2009;31:1177–91.
32. Portenoy RK, Burton AW, Gabrail N, Taylor D. A
multicenter, placebo-controlled, double-blind,
multiple-crossover study of fentanyl pectin nasal
spray (FPNS) in the treatment of breakthrough
cancer pain. Pain. 2010;151:617–24.
680 Adv Ther (2014) 31:657–682
33. Moore N, Darwish M, Amores X, Schneid H. A
review of the pharmacokinetic profile of
transmucosal fentanyl formulations. Curr Med Res
Opin. 2012;28:1781–90.
34. Darwish M, Kirby M, Robertson P Jr, et al.
Comparison of equivalent doses of fentanyl buccal
tablets and arteriovenous differences in fentanyl
pharmacokinetics. Clin Pharmacokinet.
2006;45:843–50.
35. Darwish M, Kirby M, Jiang JG, et al. Bioequivalence
following buccal and sublingual placement of
fentanyl buccal tablet 400 microg in healthy
subjects. Clin Drug Investig. 2008;28:1–7.
36. Woodcock J, Khan M, Yu LX. Withdrawal of generic
budeprion for nonbioequivalence. N Engl J Med.
2012;367:2463–5.
37. Bredenberg S, Duberg M, Lennerna¨s B, et al. In vitro
and in vivo evaluation of a new sublingual tablet
system for rapid oromucosal absorption using
fentanyl citrate as the active substance. Eur J
Pharm Sci. 2003;20:327–34.
38. Grassin-Delyle S, Buenestado A, Naline E, et al.
Intranasal drug delivery: an efficient and non-
invasive route for systemic administration: focus
on opioids. Pharmacol Ther. 2012;134:366–79.
39. Caraceni A, Hanks G, Kaasa S, European Association
for Palliative Care (EAPC), et al. Use of opioid
analgesics in the treatment of cancer pain:
evidence-based recommendations from the EAPC.
Lancet Oncol. 2012;13:e58–68.
40. Mercadante S, Villari P, Ferrera P, et al.
Transmucosal fentanyl vs intravenous morphine
in doses proportional to basal opioid regimen for
episodic-breakthrough pain. Br J Cancer.
2007;96:1828–33.
41. Mercadante S, Villari P, Ferrera P, et al. Safety and
effectiveness of intravenous morphine for episodic
(breakthrough) pain using a fixed ratio with the
oral daily morphine dose. J Pain Symptom Manag.
2004;27:352–9.
42. Pain therapy: Fans in Italy are 4 times more





43. Mercadante S. Pharmacotherapy for breakthrough
cancer pain. Drugs. 2012;72:181–90.
44. Italian Law n. 38 of 2010. Available from: http://
www.salute.gov.it/imgs/C_17_pubblicazioni_1487_
allegato.pdf. Accessed February 25, 2014.
45. Palliative Care and Pain Therapy—Reports to Italian
Parliament. Available from: http://www.salute.gov.
it/portale/temi/p2_6.jsp?lingua=italiano&id=3761
&area=curePalliativeTerapiaDolore&menu=legge.
Accessed February 25, 2014.
46. Opioids in palliative care: safe and effective
prescribing of strong opioids for pain in palliative
care of adults. NICE Clinical Guidelines, No. 140.
National Collaborating Centre for Cancer (UK).
Cardiff (UK): National Collaborating Centre for
Cancer (UK); 2012 May.
47. Vissers D, Stam W, Nolte T, Lenre M, Jansen J.
Efficacy of intranasal fentanyl spray versus other
opioids for breakthrough pain in cancer. Curr Med
Res Opin. 2010;26:1037–45.
48. Fallon M, Reale C, Davies A, et al. Efficacy and
safety of fentanyl pectin nasal spray compared with
immediate-release morphine sulfate tablets in the
treatment of breakthrough cancer pain: a
multicenter, randomized, controlled, double-
blind, double-dummy multiple-crossover study.
J Support Oncol. 2011;9:224–31.
49. Bhala N, Emberson J, Merhi A, et al. Vascular and
upper gastrointestinal effects of non-steroidal anti-
inflammatory drugs: meta-analyses of individual
participant data from randomised trials. Lancet.
2013;382:769–79.
50. Zeppetella G. Dynamics of breakthrough pain vs.
pharmacokinetics of oral morphine: implications
for management. Eur J Cancer Care (Engl).
2009;18:331–7.
51. Coluzzi PH, Schwartzberg L, Conroy JD, et al.
Breakthrough cancer pain: a randomized trial
comparing oral transmucosal fentanyl citrate
(OTFC) and morphine sulfate immediate release
(MSIR). Pain. 2001;91:123–30.
52. Bornemann-Cimenti H, Wejbora M, Szilagyi IS,
Sandner-Kiesling A. Fentanyl for the treatment of
tumor-related breakthrough pain. Dtsch Arztebl
Int. 2013;110:271–7.
53. Davies A, Zeppetella G, Andersen S, et al. Multi-
centre European study of breakthrough cancer pain:
pain characteristics and patient perceptions of
current and potential management strategies. Eur
J Pain. 2011;15:756–63.
54. England R, Manderson C, Zadora-Chrzastowska S,
et al. How practical are transmucosal fentanyl
products for breakthrough cancer pain? Novel use
of placebo formulations to survey user opinion.
BMJ Support Palliat Care. 2011;1:349–51.
55. Mercadante S, Ferrera P, Adile C, Casuccio A.
Fentanyl buccal tablets for breakthrough pain in
Adv Ther (2014) 31:657–682 681
highly tolerant cancer patients: preliminary data on
the proportionality between breakthrough pain
dose and background dose. J Pain Symptom
Manag. 2011;42:464–9.
56. Zucco F. Gli Hospice in Italia 2010: seconda
rilevazione ufficiale. Bologna: ed. Bononia
University Press, Settembre 2010, pp 1–420.
57. Fanelli C, Ventriglia G (eds). Il dolore cronico in
medicina generale. Ministero della Salute 2010.
58. Le 10 Raccomandazioni. Decreto Direttore Generale
Sanita`, Regione Lombardia, n. 23454, 30/12/2004
con Oggetto: Determinazioni per la costituzione del
Comitato Ospedale Senza Dolore (COSD) presso le
Strutture Sanitarie di ricovero e cura e adozione del
‘‘Manuale Applicativo per la realizzazione
dell’Ospedale senza Dolore’’. pag. 22. Available
from: http://www.fedcp.org/pdf/ospedale_senza_
dolore.pdf. Accessed February 25, 2014.
682 Adv Ther (2014) 31:657–682
